C. Russell Trenary III - 06 Dec 2021 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: CEO and President, Director
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol: OTLK
Transactions as of: 06 Dec 2021
Net transactions value: +$34,750
Form type: 4
Filing time: 06 Dec 2021, 16:27:50 UTC
Previous filing: 02 Dec 2021
Next filing: 04 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Purchase	$34,750	+25,000	+250%	$1.39	35,000	06 Dec 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.